Multi-Center Molecular Diagnosis And Host Response Of Respiratory Viral Infections In Pediatric Transplant Recipients
What is the goal of the study?
Early and accurate diagnosis of RVI in hematopoietic cell transplant (HCT) and Solid Organ Transplant (SOT) is paramount to improving outcomes, but current diagnostic tests have substantial limitations. This study will utilize the latest molecular technologies for direct viral detection and sequencing as well as cutting-edge assays to define host immune responses to define, for the first time, a large-scale predictive model of risk of RVI in pediatric HSCT and SOT. This could guide clinical management, including more aggressive reduction of immunosuppressive therapy if feasible and early antiviral (including mAb) therapy. Combined results will lead to the first-ever evidence-based pediatric guidelines designed to reduce RVI-related morbidity and mortality. The model can also be applied in the future to other RVI viral pathogens, and our PIDTRAN data will serve a critical function to study immune responses
Who can participate in the study?
Please contact the study team listed below to learn more.